Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Osteoporosis treatment studied by Amgen in head to head trial

Osteoporosis treatment studied by Amgen in head to head trial

25th January 2008

Amgen has released the results of a double-blind study examining the effects on bone mineral density of two different treatments on postmenopausal women.

The effects of subcutaneous injections of denosumab – given twice yearly – were compared to weekly oral doses of alendronate in a head to head, double-blind study.

Running for a total of one year, the study found that the denosumab treatment yielded greater gains in terms of bone mineral density than the oral dose of alendronate.

“We are very encouraged by the results of this head to head study directly comparing denosumab with alendronate, a widely used osteoporosis treatment, said Dr Roger M Perlmutter, the executive vice-president of research and development at Amgen.

He added that the complete analysis of data from the blind trial will be presented in a forum for peer review later on in the year.

Further to this, Dr Perlmutter noted that Amgen was looking forward to seeing the results of a study into the ability of denosumab to reduce bone-fracture risk in postmenopausal women with osteoporosis.

Amgen this week released financial results for the 2007, recording a revenue increase of four per cent to $14.8 billion (7.47 billion pounds).

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.